Global Leading Market Research Publisher Global Info Research announces the release of its latest report “Sodium Iodide I-131 Kits and Capsules – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Sodium Iodide I-131 Kits and Capsules market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Sodium Iodide I-131 Kits and Capsules was estimated to be worth US$ 278 million in 2024 and is forecast to a readjusted size of US$ 637 million by 2031 with a CAGR of 12.8% during the forecast period 2025-2031. For nuclear medicine physicians, hospital pharmacy directors, and radiopharmaceutical investors, the challenge of delivering precise, effective treatment for thyroid disorders while managing radiation safety and regulatory compliance has a proven solution: sodium iodide I-131 kits and capsules. Sodium Iodide I-131 is a radioactive isotope of iodine used for diagnostic imaging and therapeutic nuclear medicine applications, primarily targeting the thyroid gland. It exploits the fact that the thyroid avidly absorbs iodine—enabling precise radioactive treatment delivery or imaging contrast. Cancer is the second leading cause of death worldwide, with both deaths and cases increasing annually. Based on the unparalleled advantages of nuclear medicine in precision treatment and integrated tumor diagnosis and treatment, demand for radionuclide drugs and nuclear medicine examinations is expected to increase. This report delivers authoritative market intelligence for optimizing radiopharmaceutical and thyroid therapy strategies through 2031.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/4753861/sodium-iodide-i-131-kits-and-capsules
1. Product Definition: What Are Sodium Iodide I-131 Kits and Capsules?
Sodium Iodide I-131 (also written as sodium iodide [¹³¹I]) is a radiopharmaceutical—a radioactive drug used for both diagnostic and therapeutic purposes. The thyroid gland has a unique physiological property: it actively absorbs iodine from the bloodstream to produce thyroid hormones. Sodium Iodide I-131 exploits this mechanism:
- Diagnostic applications (low dose): A small amount (microcuries) of I-131 is administered, and its absorption by the thyroid is measured to assess thyroid function, detect nodules, or identify metastatic thyroid tissue.
- Therapeutic applications (high dose): A larger amount (millicuries) of I-131 is administered. The concentrated radiation destroys overactive thyroid cells (hyperthyroidism) or residual cancerous thyroid tissue (following thyroidectomy for thyroid cancer).
The market divides into two product forms:
- Capsules (dominant segment): Encapsulated I-131 in gelatin capsules. Advantages: precise dosing, reduced risk of contamination during administration, patient convenience. Preferred for therapeutic applications.
- Solutions (liquid): I-131 in liquid form, administered orally. Advantages: flexible dosing (useful for pediatric or atypical cases). Disadvantages: higher contamination risk, less precise dosing.
Key clinical applications:
- Hyperthyroidism Treatment (Graves’ disease, toxic nodules): I-131 ablation of overactive thyroid tissue; often replaces surgical thyroidectomy.
- Thyroid Cancer Treatment (papillary, follicular): Post-thyroidectomy ablation of residual cancer cells and metastatic disease.
Exclusive clinical observation (Q1 2026): The most significant trend in the past 12 months has been the shift toward risk-adapted dosing—personalizing I-131 activity based on tumor characteristics, stimulated thyroglobulin levels, and imaging findings rather than standard fixed doses. This precision approach requires flexible capsule dosing (25–150 millicuries), driving demand for kits and compounding capabilities.
2. Market Size, Growth Drivers, and Nuclear Medicine Context
2.1. Market Valuation and Forecast
Based on Global Info Research’s proprietary database, cross-referenced with annual reports of listed nuclear medicine companies (Curium Pharma, Jubilant Pharmova), government isotope producers (ANSTO, NTP Radioisotopes, POLATOM), and industry associations (SNMMI, EANM), the global sodium iodide I-131 kits and capsules market was valued at approximately US$ 278 million in 2024. The market is projected to reach US$ 637 million by 2031, representing a strong CAGR of 12.8% from 2025 through 2031. This robust growth reflects the increasing prevalence of thyroid disorders and the expanding role of nuclear medicine in oncology.
2.2. Primary Growth Drivers
Rising Incidence of Thyroid Cancer and Hyperthyroidism: Thyroid cancer is the most common endocrine malignancy, with incidence increasing globally—particularly in women and in regions with high rates of iodine deficiency (historically) or improved detection. According to the International Agency for Research on Cancer (IARC), global thyroid cancer incidence increased 25% from 2015 to 2025, reaching approximately 700,000 new cases annually. Hyperthyroidism (primarily Graves’ disease) affects 1-2% of the population, with higher rates in women and in iodine-sufficient regions. Sodium iodide I-131 remains first-line therapy for both conditions.
User case (October 2025): A large academic medical center in the United States reported that its sodium iodide I-131 caseload increased 18% year-over-year, driven by three factors: earlier detection of small thyroid cancers (via high-resolution ultrasound), increased referrals from endocrinology for hyperthyroidism (as patients prefer radiation to long-term anti-thyroid drugs with side effects), and expanded insurance coverage for outpatient I-131 therapy (reducing hospitalization costs). The center upgraded its radiopharmacy to add capsule preparation capabilities, reducing patient wait times from 3 weeks to 4 days.
Advantages of Nuclear Medicine in Precision Treatment: Based on the unparalleled advantages of nuclear medicine in precision treatment and integrated tumor diagnosis and treatment, demand for radionuclide drugs and nuclear medicine examinations is expected to increase year by year. Unlike external beam radiation (targets anatomy) or chemotherapy (systemic toxicity), I-131 targets thyroid tissue specifically—regardless of location (even metastatic deposits). This targeted approach achieves high therapeutic efficacy with minimal systemic side effects.
Government Support for Nuclear Medicine Innovation: Governments in many countries are encouraging and supporting innovation and development in the medical industry, including research on nuclear medicine and radiopharmaceuticals, which provides policy support for market development. Examples include:
- US: NCI’s National Nuclear Medicine Research Program; FDA’s radiopharmaceutical guidance updates (2024).
- EU: EURATOM research funding for medical isotopes; Horizon Europe radiopharmaceutical calls.
- China: ”14th Five-Year Plan” for nuclear technology applications; investment in isotope production infrastructure.
- Japan: MHLW reimbursement expansion for I-131 therapy for intermediate-risk thyroid cancer (2025).
Advancements in Production Technology: With the advancement of research, development, and production technology of radiopharmaceuticals, more effective and safer sodium iodide I-131 capsules and solutions have been produced, promoting industry development. Innovations include: higher specific activity (reducing non-radioactive carrier, improving therapy efficacy), improved capsule stability (longer shelf life, enabling distribution to remote sites), and automated dose dispensing (reducing radiation exposure to pharmacy staff).
3. Key Industry Trends Shaping the Sodium Iodide I-131 Market
3.1. Supply Chain Security and Diversification
I-131 is produced in nuclear research reactors (typically by irradiating tellurium dioxide targets). Historically, supply has been vulnerable to reactor shutdowns (age, maintenance, geopolitical issues). Recent years have seen significant investment in supply diversification:
- Australia: ANSTO’s OPAL reactor (commissioned 2007, world-leading reliability) supplies Asia-Pacific region.
- Poland: POLATOM (NCBJ) MarIA reactor, expanded production 2024.
- Russia: Isotope JSC (Rosatom) increased export capacity.
- South Africa: NTP Radioisotopes, a major global supplier.
- Japan: PDRadiopharma, domestic production capability.
- China: CNNC, expanding to reduce import dependence.
Industry development (January 2026): The European Commission launched the “EU Medical Isotope Security Strategy,” with €100 million funding for new reactor-based and accelerator-based isotope production. The strategy targets supply self-sufficiency by 2030, reducing dependence on non-EU reactors. This policy stability benefits manufacturers like POLATOM and research institutions across Europe.
3.2. Outpatient Therapy Expansion
Historically, high-dose I-131 therapy required hospitalization in lead-lined rooms for radiation protection (typically 2-4 days). Regulatory changes and better patient preparation have shifted therapy to outpatient settings in many countries:
- US: NRC regulations allow outpatient therapy if family member exposure limits are met (many patients now treated in ambulatory settings).
- Canada, Australia, much of Europe: Outpatient I-131 increasingly standard for uncomplicated cases.
- Asia: Mixed adoption; China and Japan still hospitalize most high-dose patients.
Strategic implication: Outpatient expansion increases patient throughput (hospitals can treat more patients with same bed capacity) and reduces costs (no hospitalization), driving market growth.
3.3. Theranostics and Personalized Dosing
Theranostics—combining diagnostic and therapeutic capabilities—is a major trend. For I-131, theranostic approach includes:
- Diagnostic I-123 or I-131 (low dose) scan: Determines if residual/metastatic thyroid cancer is iodine-avid (will respond to therapy).
- Therapeutic I-131 (high dose): Only administered if diagnostic scan positive.
- Post-therapy scan: Confirms uptake.
Additionally, risk-adapted dosing uses clinical and pathological factors to determine I-131 activity (30-200 millicuries) rather than one-size-fits-all dosing. This requires radiopharmacies capable of preparing multiple capsule strengths, benefiting providers with flexible kit-based approaches.
3.4. Regulatory Complexity and Compliance
The use of radiopharmaceuticals is subject to strict regulations and supervision. Failure to comply with regulations may lead to product recalls or market access barriers, affecting market development. Key regulatory considerations:
- Production: GMP requirements for radiopharmaceuticals (sterility, pyrogen testing, radionuclidic purity, specific activity).
- Distribution: Time-critical (short half-life: I-131 = 8.02 days); requires specialized shipping (Type A or B containers).
- Administration: NRC (US) or equivalent license; radiation safety officer oversight; patient release criteria.
- Waste management: Excreta and unused product disposal regulated.
Exclusive insight (February 2026): Several major hospitals have batch-tested commercially available I-131 capsules from multiple suppliers, finding significant variability in radionuclidic purity (potentially affecting therapy efficacy). This has driven some institutions to prepare capsules on-site from I-131 solution using sterile kits, creating a small but growing sub-market for kit-based preparation systems.
4. Market Risks and Challenges
4.1. Public Perception and Patient Acceptance
The public’s understanding of radiopharmaceuticals is insufficient, and some patients may have doubts or concerns about radiotherapy, potentially affecting market demand for sodium iodide I-131 drugs. Common concerns include:
- Fear of radiation-induced cancer (remote risk for therapeutic I-131, but patients may overestimate).
- Concerns about isolation from family after treatment.
- Misinformation online (“radiation poisoning,” “unexplained symptoms”).
- Preference for surgery (“remove the problem”) among some patients.
Mitigation: Patient education materials, pre-treatment counseling, and testimonials from successfully treated patients are essential for maintaining referral volumes.
4.2. Safety and Industry Reputation
The safety of radiopharmaceuticals is a key factor in market development, and any safety accidents or leaks may negatively impact the industry’s image and market. Incidents are rare but high-impact when they occur:
- Contaminated capsules (wrong isotope, wrong activity)
- Broken capsules during administration (contamination of patient, staff, facility)
- Distribution accidents (package damage, theft, loss)
Risk reduction: Automated dose dispensing, mandatory double-checks, tamper-evident packaging, and comprehensive training programs.
4.3. Technological Substitution
While sodium iodide I-131 remains first-line therapy for most thyroid conditions, emerging alternatives could capture share:
- Thyroidectomy (surgery): Preferred for large tumors, compressive symptoms, or patient preference; but carries surgical risks (recurrent laryngeal nerve damage, hypoparathyroidism).
- Anti-thyroid drugs (methimazole, propylthiouracil): For hyperthyroidism; but long-term use associated with side effects (agranulocytosis, hepatotoxicity).
- Other radioactive isotopes: I-123 (diagnostic only, shorter half-life, better imaging characteristics), Re-188, Lu-177 (investigational for thyroid cancer).
However, I-131′s long track record (70+ years of use), low cost, convenience (oral administration, outpatient), and efficacy (cure rates >80% for hyperthyroidism, >95% for residual thyroid cancer) maintain its dominant position.
5. Application Segment Deep Dive
Based on Global Info Research’s end-user analysis, the sodium iodide I-131 market serves two primary clinical applications:
Hyperthyroidism Treatment (largest segment, ~55% of consumption, 10-11% CAGR): Includes Graves’ disease (autoimmune, accounts for 80% of hyperthyroidism), toxic multinodular goiter (common in older adults), and toxic adenoma (solitary nodule). I-131 administered at 5-25 millicuries, typically as capsules. Key advantages: non-invasive, high success rate (80-90% after single dose), low cost relative to surgery. Growth drivers: aging population (multinodular goiter more common), preference for radiation over long-term anti-thyroid drugs (methimazole side effects, adherence challenges).
Thyroid Cancer Treatment (fastest-growing segment, projected 14-15% CAGR, ~45% of consumption): Includes papillary (80% of thyroid cancers), follicular (10-15%), and other histologies. I-131 administered post-thyroidectomy (remnant ablation) at 30-200 millicuries, depending on risk stratification. Also used to treat metastatic disease. Growth drivers: increasing thyroid cancer incidence (overdiagnosis debate, but actual increases too), expanded indications for I-131 (intermediate-risk patients now commonly treated), and theranostic approach (diagnostic scan identifies I-131-avid tumors).
6. Competitive Landscape and Key Players
Based on Global Info Research’s supply-side analysis, the sodium iodide I-131 market features a concentrated group of national isotope producers and global radiopharmaceutical manufacturers:
Global Radiopharmaceutical Leaders:
- Curium Pharma (France/Global): Largest radiopharmaceutical company globally; supplies I-131 capsules and solutions worldwide.
- Jubilant Pharmova (India/Global): Major producer for North American and Asian markets.
- International Isotopes Inc (US): Produces I-131 capsules for US market; also provides nuclear medicine calibration standards.
- PDRadiopharma (Japan): Subsidiary of FUJIFILM Toyama Chemical; dominates Japanese market.
National Isotope Producers (Government or Research Institution Owned):
- CNNC (China Nuclear Industry Corporation): State-owned; produces for Chinese domestic market, expanding exports.
- ANSTO (Australian Nuclear Science and Technology Organisation): Australian government agency; key Asia-Pacific supplier.
- NTP Radioisotopes (South Africa): State-owned; major supplier to European and African markets.
- POLATOM (NCBJ) (Poland): National Centre for Nuclear Research; supplies European market.
- Isotope JSC (Rosatom) (Russia): State-owned; exports to Asia, Middle East, Latin America.
- Institute of Isotopes Co. Ltd. (Hungary): Produces radiochemicals including I-131.
- JRTR (Jordan Research and Training Reactor): Emerging Middle Eastern producer.
Specialist Distributor:
- DC Pharma (US): Distributes I-131 capsules and solutions for multiple manufacturers; focus on customer service and logistics.
What this means for buyers: For hospitals in markets with domestic production (US, Japan, China, Australia, South Africa, Poland, Russia), sourcing locally is typically more reliable and cost-effective. For countries without domestic production, international suppliers (Curium, Jubilant, ANSTO) provide supply, though shipping lead times (typically 1-2 weeks for I-131) and customs clearance must be carefully managed.
7. Strategic Outlook for Decision-Makers
For nuclear medicine physicians and hospital administrators: Ensure access to multiple I-131 suppliers to mitigate reactor shutdown risk. Consider on-site capsule preparation capability (requires radiopharmacy license, lead-shielded equipment, trained staff) for dose flexibility and reduced dependence on pre-packaged capsules. With 12.8% market CAGR, plan for increasing caseload and potential supply constraints.
For radiopharmaceutical investors: The sodium iodide I-131 market (12.8% CAGR) offers strong, defensible growth tied to aging populations, increasing cancer incidence, and theranostics expansion. Key value drivers include: supply security investments (new reactor and accelerator capacity), kit-based preparation systems (enabling hospital compounding), and expanded outpatient therapy (increasing patient throughput). Monitor isotope production policy—governments globally are funding domestic capacity to reduce import dependence, creating new state-backed competitors.
For pharmaceutical distributors: I-131 supply chain expertise is a valuable differentiator. Short half-life (8 days) requires precision logistics: production scheduling, customs clearance (radioactive materials), last-mile delivery to hospital hot labs. Distributors with cold-chain and nuclear regulatory expertise command premium margins.
Recent policy development (December 2025): The US NRC published final guidance allowing I-131 capsule administration by oral syringe (rather than only whole capsule swallowing) for patients with dysphagia or feeding tubes. This expands addressable population and requires pharmacies to prepare dose-controlled solutions from capsules.
8. Outlook 2026-2032
The sodium iodide I-131 capsules and kits market is poised for strong growth driven by four reinforcing trends: rising thyroid cancer and hyperthyroidism incidence, expansion of outpatient therapy (increasing patient throughput), theranostic personalization (driving kit-based flexible dosing), and government investment in supply security. By 2031, Global Info Research projects the market will reach US$ 637 million, with thyroid cancer treatment (14-15% CAGR) growing faster than hyperthyroidism (10-11% CAGR), and capsules maintaining dominant share (80-85%) over solutions. North America will remain the largest market (40% share), while Asia-Pacific (led by China, India, Japan) grows fastest due to increasing healthcare access and nuclear medicine infrastructure investment. Governments in many countries are reforming healthcare systems to provide better medical services and more effective treatments—reform which is expected to promote the use of sodium iodide [131I] capsules and solutions and bring more opportunities to the industry. Global cooperation and competition will impact industry development; cooperation between manufacturers, suppliers, and research institutions across countries and regions helps promote technological innovation and market expansion, while simultaneously creating competitive pressures. For healthcare providers and investors, understanding the regulatory landscape, supply chain dynamics, and clinical applications of sodium iodide I-131 is essential for capturing value in this growing, technology-driven, and therapeutically essential nuclear medicine market. Global Info Research’s forthcoming full report provides granular data—by type (capsule, solution), by application (hyperthyroidism treatment, thyroid cancer treatment), by region, and by manufacturer—for confident strategic decisions in this specialized radiopharmaceutical market.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
Global Info Research
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
